By David Graziano, Head of Retail Network at GoodRx
If you were an independent pharmacy losing money every time you filled a brand prescription, how long could you keep your doors open? For thousands of local pharmacies across the country, that’s not a hypothetical question. It’s a daily reality given industry economics, especially when dispensing high-cost, high-demand medications like GLP-1s. The math simply doesn’t work, and it’s putting both pharmacies and patients at risk.
GoodRx created Community Link to change that, bringing transparency and predictability to both brand and generic dispensing so independent pharmacies can serve patients sustainably and with confidence.
The GLP-1 Paradox
GLP-1 medications, such as Ozempic and Wegovy, have transformed diabetes and weight management, but they’ve also exposed how broken and unsustainable pharmacy reimbursement in the healthcare industry has become. Across the country, independents are filling prescriptions for these life-changing therapies only to find that the reimbursement they receive doesn’t even cover their cost.
This isn’t inefficiency or mismanagement. It’s the result of opaque pricing systems that leave pharmacies with little control over how they’re reimbursed. Over time, the losses add up, forcing pharmacies to question whether they can keep critical medications on their shelves. When they can’t, they often have to refer people to other pharmacies and risk losing that patient to a competitor for all their scripts.
This is the paradox independent pharmacies face today: high demand for life-changing therapies, but a reimbursement system that penalizes them for providing access.
A Transparent Model That Works
Pharmacies shouldn’t have to choose between serving patients and staying solvent. That belief is what inspired Community Link, a program that brings predictability and transparency to independent pharmacy reimbursement.
Here’s how it works for brand medications: manufacturers buy down the patient price, and those funds flow directly back to the pharmacy through GoodRx. The manufacturer covers GoodRx’s administrative fee, ensuring the pharmacy retains 100% of its reimbursement. GoodRx currently has cash prices for brand medications such as Ozempic, Wegovy, Lantus, a Humira biosimilar, and medical devices, such as Dexcom.
“If you’re a manufacturer launching D2C, you must have a solution for independent pharmacies—and Community Link is that solution. And if you’re an independent pharmacy not yet participating with GoodRx for these medications, you’re leaving real value on the table. You owe it to your business to take a closer look,” said Tom DePietro, PharmD, Owner of DePietro’s Pharmacy in Dunmore, PA.
Patients Benefit Too
For patients, this model delivers the same transparency. As Affordable Care Act marketplace subsidies and Medicaid support may leave more Americans uninsured or facing higher out-of-pocket costs, more people are paying cash for prescriptions. With Community Link, patients know what they’ll pay upfront, without hidden fees or last-minute price changes.
This alignment means affordability for patients and sustainability for pharmacies go hand in hand. By simplifying how funds flow from manufacturers to pharmacies, Community Link creates a model where everyone benefits: patients save, pharmacies earn fairly, and manufacturers keep their medications accessible through trusted local providers.
Beyond GLP-1s
While GLP-1s highlight the urgency of the problem, they’re far from the only pain point. High acquisition costs and unpredictable reimbursement affect many brand medications, from cardiovascular and autoimmune therapies to asthma and mental health treatments.
Community Link addresses this issue across brand medications with GoodRx discounted cash prices, ensuring independent pharmacies are supported across key therapeutic areas. By linking reimbursement directly to acquisition cost, the program supports trust and financial stability for independent pharmacy economics.
And the support doesn’t stop with brand drugs. Community Link also helps with generic dispensing, with a predictable cost-plus pricing model based on NADAC. This eliminates the lack of transparency in the industry that makes it challenging for independent pharmacists to manage their businesses.
With predictable margins, pharmacies can stock and dispense both brand and generic therapies confidently, while patients continue receiving care from the pharmacists who know them best.
Building A Sustainable Future
The goal of Community Link isn’t just to fix reimbursement for one category of drugs. It’s to demonstrate a better model for pharmacy economics. By aligning transparency, affordability, and sustainability, the program strengthens the entire care ecosystem.
As new, high-cost therapies enter the market and brand drugs make up an increasing share of prescriptions, independent pharmacies need a model that makes sense both economically and operationally. Community Link provides that structure, helping to support both pharmacy viability and patient access.
GLP-1s may have brought the problem into focus, but they’re not the end of the story. Independent pharmacies deserve a fair, transparent way to serve their patients and Community Link is demonstrating how that future can look.
At GoodRx, our mission is to help sustain the pharmacies that anchor local care, enable manufacturers to reach the patients who benefit most from their treatments, and connect consumers to affordable medications — especially as more Americans turn to cash options for their prescriptions.
Independent pharmacies looking to unlock the value of GoodRx for their businesses can visit GoodRx Community Link.